Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.

The presentations will be available via live audio webcast on the Company’s website. Archived replays will also be located on the Company’s site following the events. The presentation date and time is subject to change. The most up to date information will be available on the Company’s website.